Development of a rapid, point of care screening test for Staphylococcus aureus for acute patient admissions
Lead Participant:
CLARITY BIOSOLUTIONS LIMITED
Abstract
Modified Screening Guidance provided to the NHS removes the mandatory element of screening for MRSA. Commentary on the proposal from 4 hospital infection control groups suggest change away from universal screening can be expected to lead to a greater number of undetected MRSA patients, with a potentially greater transmission risk. This project develops Kingston University’s patent-pending fluorescence probe (LGX) that can detect SA at low bacterial concentration within 30 minutes, without the need for microbiological culturing and at a reduced cost. It will develop the technology from a bench test to a prototype assay validated by means of a clinical/usability study.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
CLARITY BIOSOLUTIONS LIMITED | £49,992 | £ 34,994 |
  | ||
Participant |
||
KINGSTON UNIVERSITY | ||
KINGSTON UNIVERSITY | £49,443 | £ 49,443 |
INNOVATE UK |
People |
ORCID iD |
Hugh Ballantine Dykes (Project Manager) |